1448 related articles for article (PubMed ID: 19808266)
21. The efficacy of aliskiren, a direct renin inhibitor, in the treatment of hypertension.
Gradman AH; Traub D
Rev Cardiovasc Med; 2007; 8 Suppl 2():S22-30. PubMed ID: 17401313
[TBL] [Abstract][Full Text] [Related]
22. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
23. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
Roig E; Perez-Villa F; Morales M; Jiménez W; Orús J; Heras M; Sanz G
Eur Heart J; 2000 Jan; 21(1):53-7. PubMed ID: 10610744
[TBL] [Abstract][Full Text] [Related]
25. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
Seed A; Gardner R; McMurray J; Hillier C; Murdoch D; MacFadyen R; Bobillier A; Mann J; McDonagh T
Eur J Heart Fail; 2007 Nov; 9(11):1120-7. PubMed ID: 17945530
[TBL] [Abstract][Full Text] [Related]
26. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of microalbuminuria in chronic heart failure patients.
van de Wal RM; Asselbergs FW; Plokker HW; Smilde TD; Lok D; van Veldhuisen DJ; van Gilst WH; Voors AA
J Card Fail; 2005 Oct; 11(8):602-6. PubMed ID: 16230263
[TBL] [Abstract][Full Text] [Related]
28. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.
Sidik NP; Solomon SD; Latini R; Maggioni AP; Wright M; Gimpelewicz CR; Pitt B; McMurray JJ
Cardiovasc Drugs Ther; 2011 Aug; 25(4):315-21. PubMed ID: 21779784
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
[TBL] [Abstract][Full Text] [Related]
30. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.
Chrysant SG
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):305-14. PubMed ID: 18327992
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
[TBL] [Abstract][Full Text] [Related]
34. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.
Chang J; Yang W; Kahler KH; Fellers T; Orloff J; Bensimon AG; Yu AP; Fan CP; Wu EQ
Am J Cardiovasc Drugs; 2011; 11(1):21-32. PubMed ID: 21142294
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
[TBL] [Abstract][Full Text] [Related]
37. First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
Sawhney JP
Indian Heart J; 2010; 62(1):49-56. PubMed ID: 21180035
[TBL] [Abstract][Full Text] [Related]
38. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
[TBL] [Abstract][Full Text] [Related]
39. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
Zeymer U; Dechend R; Deeg E; Kaiser E; Senges J; Pittrow D; Schmieder R;
Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
[TBL] [Abstract][Full Text] [Related]
40. Renin inhibition in hypertension.
Gradman AH; Kad R
J Am Coll Cardiol; 2008 Feb; 51(5):519-28. PubMed ID: 18237679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
